Introduction: Pseudomonas aeruginosa is one of the most prevalent nosocomial pathogens that cause a life-threatening infection. One of the important characteristics of P. aeruginosa is biofilm formation and the most studied bacterium related to biofilm formation so far. The biofilm formation and beta-lactamases production synergistically contribute to the extensive dissemination of multi-drug resistant strains. Aim: The present study was conducted to identify, biofilm-producing isolates of P. aeruginosa along with their antibiotic resistance pattern and ESBL and MBL production and to analyze their antibiogram. Materials and methods: Various clinical specimens were collected and totally 82 clinical isolates of P. aeruginosa were included in this study. Biofilm producing isolates were identified by the tube adherence method. Results: Among the total, 22 [26.83%] isolates were biofilm producers and the maximum number was obtained from blood [100%], followed by ETT [75%], and Drain [66.67%]. Biofilm producing isolates were showing more resistance in comparison to non-biofilm producers. All isolates of P. aeruginosa were sensitive to colistin and polymyxin B. Association of ESBL production and biofilm formation found to be statistically significant [p < 0.002], which was a contrast to association of MBL production and biofilm formation. Conclusion: High-level resistance to antimicrobial agents is a characteristic feature of infection caused by biofilm and lead to chronic infections. Knowledge about these biofilm-producing isolates is important in the clinical setting to eradicate these chronic and life-threating infections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.